Beatriz Grinsztejn - Concepedia

Author

Beatriz Grinsztejn

Also Known As

Albert Y. Liu, B Grinsztejn, B. Grinsztejn, Badal-Faesen, Sharlaa, Beatriz G. Grinsztejn, Beatriz GRINSZTEJN, Beatriz Gilda Grinsztejn, Beatriz Gilda J. Grinsztejn, Beatriz Gilda Jegerhorn Grinsztein, Beatriz Gilda Jegerhorn Grinsztejn

743

Publications

34.3K

Citations

H-Index

218

Concepts

All Affiliations

Fundação Oswaldo Cruz Instituto Evandro Chagas Johns Hopkins University University of California, Los Angeles University of California, San Francisco

About

Beatriz Grinsztejn is an author at Fundação Oswaldo Cruz specializing in medicine, hiv, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	72	6.9K
2	Public Health	28	54	2.8K
3	Health Sciences	7	7	225
4	Nursing	2	2	83
5	Natural Sciences	1	1	27

Beatriz Grinsztejn

343

Publications

30.4K

Citations

H-Index

Page 1

	Year	Citations
Prevention of HIV-1 Infection with Early Antiretroviral Therapy Myron S. Cohen, Ying Qing Chen, Marybeth McCauley, New England Journal of Medicine	2011	6.9K
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 Jerald Sadoff, Glenda Gray, An Vandebosch, New England Journal of Medicine	2021	2.5K
Antiretroviral Therapy for the Prevention of HIV-1 Transmission Myron S. Cohen, Ying Qing Chen, Marybeth McCauley, New England Journal of Medicine	2016	1.7K
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women Raphael J. Landovitz, Deborah Donnell, Meredith E. Clement, New England Journal of Medicine	2021	773
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial Beatriz Grinsztejn, Bach-Yen Nguyen, Christine Katlama, The Lancet Multidrug-resistant VirusTreatment And PreventionAntiviral Drug DevelopmentAntiviral TherapyVirology	2007	566
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial José Valdez Madruga, Pedro Cahn, Beatriz Grinsztejn, The Lancet Treatment-experienced Hiv-1-infected PatientsTreatment And PreventionHuman RetrovirusImmunologyClinical Trials	2007	515
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study Pedro Cahn, Anton Pozniak, Horacio Mingrone, The Lancet Treatment And PreventionWeek 48Antiviral Drug DevelopmentAntiviral TherapyDolutegravir Versus Raltegravir	2013	507
Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial Beatriz Grinsztejn, Mina C. Hosseinipour, Heather J. Ribaudo, The Lancet Infectious Diseases Hptn 052Hiv/aids CounsellingTreatment And PreventionHuman RetrovirusAntiviral Therapy	2014	507
Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study Benjamin R. Bavinton, Angie N. Pinto, Nittaya Phanuphak, The Lancet HIV Serodiscordant Male CouplesSexual HealthViral SuppressionTreatment And PreventionHuman Retrovirus	2018	507
Mpox in people with advanced HIV infection: a global case series Andrea Alemany, Michael Marks, Jezer I Lezama Mora, The Lancet Advanced Hiv InfectionSexual HealthTreatment And PreventionHuman RetrovirusGlobal Health	2023	452

Page 1